Morphofunctional changes in the skin in topical tacrolimus therapy of localized psoriasis

Abstract

The effect of topical tacrolimus ointment on the morphological and cutaneous changes in patients with localized psoriasis was studied by noninvasive diagnostic methods (laser confocal microscopy, laser Doppler flowmetry). The results confirmed the efficiency of topical tacrolimus ointment, comparable to that of corticosteroids.

Keywords

psoriasis / tacrolimus / laser confocal / microscopy / laser Doppler flowmetry

References

[1] Prinz J. Identification of the T cells causing psoriasis. Dermatology at the Millenium: abstract book of the 14th Regional Conference of Dermatology, Kuala Lumpur, 26-30 July 2000: 484-91.

[2] Kormeili T., Lowe N.J., Yamauchi P.S. Psoriasis: immunopathogenesis and evolving immunomodulators and systemic therapies; U.S. experiences. Topical Rev. Br. J. Dermatol. 2004; 151(1): 3-15.

[3] Menter M.A., guest ed. Psoriasis for the clinician: a new therapeutics era ("the biologies") beckons. J. Am. Acad. Dermatol. 2003; 49 (Suppl. 2): S39-142.

[4] Sabat R., Philipp S., Hoflich C., Kreutzer S., Wallace E., Asadullah K., et al. Immunopathogenesis of psoriasis. Exp. Dermatol. 2007; 16(10): 779-98.

[5] Кунгуров Н.В., Филимонкова Н.Н., Тузанкина И.А. Псориатическая болезнь. Екатеринбург; 2002.

[6] Finlay A.Y. Current severe psoriasis and the rule of tens. Br. J. Dermatol. 2005; 152(5): 861-7.

[7] Luba K.M., Stulberg D.L. Chronic plaque psoriasis. Am. Fam. Physician. 2006; 73(4): 636-44.

[8] Бакулев А.Л. Такролимус: 10 лет успешного применения в клинической практике. Вестник дерматологии и венерологии. 2010; 6: 23-37.

[9] Ruzicka T., Assmann T., Homey B. Tacrolimus: the drug for the turn of the millennium? Arch. Dermatol. 1999; 135(5): 574-80.

[10] Lazarous M.C., Kerdel F.A. Topical tacrolimus Protopic. Drugs Today (Barc). 2002; 38(1): 7-15.

[11] Mollison K. W., Fey T.A., Gauvin D.M., Kolano R.M., Sheets M.P., Smith M.L., et al. A macrolactam inhibitor of T helper type 1 and T helper type 2 cytokine biosynthesis for topical treatment of inflammatory skin diseases. J. Invest. Dermatol. 1999; 112(5): 729-38.

[12] Martin Ezquerra G., Sanchez Regana M., Herrera Acosta E., Umbert Millet P. Topical tacrolimus for the treatment of psoriasis on the face, intertriginous areas and corporal plaques. J. Drugs Dermatol. 2006; 5(4): 334-6.

[13] Michel G., Kemeny L., Homey B., Ruzicka T. FK506 in the treatment of inflammatory skin disease: promises and perspectives. Immunol. Today. 1996; 17(3):106-8.

[14] Gupta A.K., Adamiak A., Chow M. Tacrolimus: a review of its use for management of dermatoses. J. Eur. Acad. Dermatol. Venereol. 2002; 16(2): 100-14.

[15] Fleisher A.B. Treatment of atopic dermatitis: Role of tacrolimus ointment as a topical noncorticosteroid therapy. J. Allergy Clin. Immunol. 1999; 104(3): 126-30.

[16] Lawrence I.D. Tacrolimus (FK506): experience in dermatology. Dermatol. Therapy. 1998; 5: 74-84.

[17] Bieber T. Topical tacrolimus (FK506): a new milestone in the management of atopic dermatitis. J. Allergy Clin. Immunol. 1998; 102(4, Pt 1): 555-7.

[18] Bekersky I., Ohara K., Dressler D.E., Kuroda Y., Sambuco C.P. An evaluation of the phototoxicity of tacrolimus (FK506) ointment in hairless mice. Int. J. Toxicol. 1998; 17(5): 541-50.

[19] Thaci D., Reitamo S., Ensenat M.A.G, Moss C., Boccaletti V., Cainelli T., et al. Proactive disease management with 0,03% tacrolimus ointment for children with atopic dermatitis: results of a randomized, multicenter, comparative study. Br. J. Dermatol. 2008; 159(6): 1348-56.

RIGHTS & PERMISSIONS

Eco-Vector